Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Statistical Evaluation of Drug Safety Data
H Amy Xia, Qi Jiang
Journal of Biopharmaceutical Statistics
|
January 22, 2013
The practice of pre-marketing safety assessment in drug development
Christy Chuang-Stein, H Amy Xia
Journal of Biopharmaceutical Statistics
|
August 12, 2011
Bayesian hierarchical modeling for detecting safety signals in clinical trials
H Amy Xia, Haijun Ma, Bradley P Carlin
Pharmaceutics
|
December 5, 2013
Safety monitoring in clinical trials
Bin Yao, Li Zhu, Qi Jiang, et al.
Biometrics
|
September 30, 2011
Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
Joseph G Ibrahim, Ming-Hui Chen, H Amy Xia, et al.
Frontiers in Oncology
|
February 3, 2023
Landmark mediation survival analysis using longitudinal surrogate
Jie Zhou, Xun Jiang, H Amy Xia, et al.
Biostatistics (Oxford, England)
|
May 13, 2021
Bayesian adaptive design for concurrent trials involving biologically related diseases
Matthew A Psioda, H Amy Xia, Xun Jiang, et al.
Statistics in Medicine
|
December 18, 2013
Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program
Ming-Hui Chen, Joseph G Ibrahim, H Amy Xia, et al.
Journal of Biopharmaceutical Statistics
|
March 20, 2025
Improving power in adaptive expansion of biomarker populations in phase 3 clinical trials
Guoqing Diao, Xun Jiang, Donglin Zeng, et al.
Cancer Metastasis Reviews
|
January 30, 2026
PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results
Jie Zhou, Xun Jiang, Qing Liu, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Statistical Evaluation of Drug Safety Data
H Amy Xia, Qi Jiang
Journal of Biopharmaceutical Statistics
|
January 22, 2013
The practice of pre-marketing safety assessment in drug development
Christy Chuang-Stein, H Amy Xia
Journal of Biopharmaceutical Statistics
|
August 12, 2011
Bayesian hierarchical modeling for detecting safety signals in clinical trials
H Amy Xia, Haijun Ma, Bradley P Carlin
Pharmaceutics
|
December 5, 2013
Safety monitoring in clinical trials
Bin Yao, Li Zhu, Qi Jiang, et al.
Biometrics
|
September 30, 2011
Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
Joseph G Ibrahim, Ming-Hui Chen, H Amy Xia, et al.
Frontiers in Oncology
|
February 3, 2023
Landmark mediation survival analysis using longitudinal surrogate
Jie Zhou, Xun Jiang, H Amy Xia, et al.
Biostatistics (Oxford, England)
|
May 13, 2021
Bayesian adaptive design for concurrent trials involving biologically related diseases
Matthew A Psioda, H Amy Xia, Xun Jiang, et al.
Statistics in Medicine
|
December 18, 2013
Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program
Ming-Hui Chen, Joseph G Ibrahim, H Amy Xia, et al.
Journal of Biopharmaceutical Statistics
|
March 20, 2025
Improving power in adaptive expansion of biomarker populations in phase 3 clinical trials
Guoqing Diao, Xun Jiang, Donglin Zeng, et al.
Cancer Metastasis Reviews
|
January 30, 2026
PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results
Jie Zhou, Xun Jiang, Qing Liu, et al.
Page
of 3